Index

Note: Italicized page numbers refer to figures and tables.

accessory connection, 232t
adult congenital heart disease
aortopathy, 115–20
atrioventricular septal defects, 9–23
coaeration of the aorta, 102–15
congenitally corrected transposition of
the great arteries, 76–85
Ebstein’s anomaly, 174–87
imaging in, 190–201
left ventricular outflow tract
obstruction, 87–98
pulmonary arterial hypertension, 57–73
pulmonary stenosis, 25–38
right ventricular outflow obstruction,
25–38
secundum atrial septic defect, 1–7
single-ventricle physiology, 157–71
tetralogy of Fallot, 139–53
transposition of great arteries, 126–38
ventricular septal defect, 41–53
Alagille syndrome, 35
aneurysmal dilatation of RVOT, 145, 149,
150
aneurysms, 113
aortic, 113
case, 120–21
cerebrovascular, 113
definition of, 115
identification of, 200
thoracic aortic, 117
treatment of, 118–19
angiography, 194
angiopoetin-1, 63
angiotensin receptor blockers, 83
angiotensin-converting enzyme inhibitors
(ACEI), 69, 83
anterior bridging leaflets, 19
anticoagulation, 72, 249–50
aorta
development of, 103–4
embryology of, 103–4
aortic, coarctation of, 102–15
aortic embryology/development, 103–4
associated lesions, 104
case, 102, 120–21
CT scanning, 107
definition of, 104
diagnosis, 105
echocardiogram, 106–7
electrocardiogram, 106
etiology, 104
imaging, 199–200
intervention summary, 112
interventional catheterization, 110–11
magnetic resonance imaging, 107
medical considerations, 112–13
aortic aneurysms, 113
cerebrovascular aneurysms, 113
coronary artery disease, 113
hypertension, 112
in pregnant women, 245–6
presentation, 105
prevalence, 104
recurrence of, 111
routine follow-up, 113–15
surgery, 109–10
testing, 105–7
treatment of, 107–8
aortic aneurysms, 113
aortic regurgitation, 145
aortic root, dilatation of, 149
aortic stenosis, 245
aortopathy, 115–20. See also coarctation of the aorta
connective tissue disorders, 115–18
bicuspid aortic valve, 117–18
Ehlers-Danlos syndrome, 115–16
Loeys-Dietz syndrome, 115–16
Marfan syndrome, 115–16
thoracic aortic aneurism and dissection syndrome, 117
Turner syndrome, 117
definition of, 115
medical therapy, 119
pathology of, 115
and pregnancy, 246–7
screening and monitoring, 118
surgical therapy, 119–20
treatment of, 118–19
aortopulmonary shunts, 161
arrhythmias, 221–33
case study, 221
and catheter ablation, 184–5
in congenital heart disease, 221–33
case study, 221, 233–4
prevention of, 231–3
prophylactic management of, 232f
risk of sudden death, 229–31
treatment of, 222–9
in Fontan patients, 170–71
incidence of, 222–3
in pregnant women, 251
in transposition of great arteries, 130–31
ascending aorta, 214–16
atrial baffles, 130–32
functions of, 131
leaks, 132
obstructions, 131–2
atrial fibrillation, 224f, 232f
atrial isomerism, 166–7
atrial reentry tachycardia, 224f, 232f
atrial septal defect, 195–6, 223f, 243
atrial septal defect (ASD), secundum, 1–7
anatomy of, 2–3
case, 1
closure of, 6–7
diagnosis, 4–6
cardiac catheterization, 5–6
magnetic resonance imaging, 5–6
transesophageal echocardiography, 4–5
embryology of, 2–3
natural history, 3–4
pathophysiology of, 3
patient follow-up, 7
treatment of, 6–7
atrial septation, 2–3
atrioventricular arrhythmias, 166–7
atrioventricular block, 224f, 232f
atrioventricular discordance, 78
atrioventricular nodal reentry tachycardia, 224f, 225f, 232f
atrioventricular septal defects (AVSD), 9–23
atrioventricular valve abnormalities, 21
case studies, 9–10, 22–3
clinical evaluation after repair, 22
clinical presentation, 19–20
complete, 19–21
double-orifice left atrioventricular valve, 21
echocardiographic evaluation of, 20–21
forms of, 12–14
intermediate, 14
left-to-right shunts, 243–4
partial, 14–19
pathology of, 19
atrioventricular septal defects (AVSD) (Contd.)
patient follow-up, 22–3
in pregnant women, 243–4
primum, 17–18
progressive LVOT obstruction in, 10–11
single left ventricular papillary muscle, 21
surgical repair of, 21
transitional, 12–14
unbalanced, 21
azygos vein, 136
baffles, 131–2. See also transposition of great arteries (TGA)
functions of, 131
leaks, 132
obstructions, 131–2
balloon pulmonary valvuloplasty, 32f
barbiturates, 67
Beraprost, 72
Bernoulli equation, 4
bicuspid aortic valve (BAV), 89–93. See also
left ventricular outflow tract obstruction (LVOTO)
and coarctation of the aorta, 104, 117–18
endocarditis, 92–3
intervention, 91–2
long-term follow-up, 92
pathophysiology of, 91
prevalence, 90–91
bidirectional Glenn, 163f
Blalock-Taussig shunt, 161
bone morphogenetic protein receptor II, 63
bones, 211
bosentan, 70, 73, 252
bronchial arterial collaterals, 213
bronchiectasis, 213
Bruce protocol, 31

cardiac catheterization
congenitally corrected transposition of the great arteries, 80
Ebstein’s anomaly, 182–3
Eisenmenger syndrome, 64–5
pulmonary stenosis, 30
secundum atrial septic defect, 5–6
transposition of great arteries, 137
ventricular septal defect, 49
cardiac magnetic resonance (CMR)
imaging, 30, 49, 193
cardiac silhouette, enlarged, 2f
cardiocversion, 227
“CATCH 22” syndrome, 147
catheter ablation, 184–5, 227
cavopulmonary shunts, 161–5
central pulmonary arteries, enlarged, 2f
Cerazette, 70, 254
cerebrovascular aneurysms, 113
chest x-ray, 208–20
atria, 218–20
bones, 211
in congenitally corrected transposition of the great arteries, 79
in Ebstein’s anomaly, 181
extrapulmonary soft tissue densities, 212–18
sequence for reading, 209t
coarctation of the aorta, 102–15
aortic embryology/development, 103–4
associated lesions, 104
case, 102, 120–21
CT scanning, 107
definition of, 104
diagnosis, 105
echocardiogram, 106–7
electrocardiogram, 106
etiology, 104
imaging, 199–200
intervention summary, 112
interventional catheterization, 110–11
magnetic resonance imaging, 107
medical considerations, 112–13
aortic aneurysms, 113
cerebrovascular aneurysms, 113
coronary artery disease, 113
hypertension, 112
in pregnant women, 245–6
presentation, 105
prevalence, 104
reurrence of, 111
Index 263

routine follow-up, 113–15
surgery, 109–10
testing, 105–7
treatment of, 107–8
compensated state, 66
complete atrioventricular septal defects, 19–22
clinical evaluation after repair, 22
clinical presentation of, 19–20
double-orifice left atrioventricular valve, 21
echocardiographic evaluation of, 20–21
pathology of, 19
single left ventricular papillary muscle, 21
surgical treatment of, 21
valve abnormalities in, 21
computed tomography (CT), 107, 193
conduction defects, 51
congenital heart disease (CHD), 190–201
aortopathy, 115–20
arrhythmias in, 221–33
case study, 221, 233–4
prevention of, 231–3
prophylactic management of, 232
risk of sudden death, 229–31
treatment of, 222–9
atrial septal defect, 195–6
atrioventricular septal defects, 9–23
case study, 190
chest x-ray in, 208–20
atria, 218–20
bones, 211
extrapulmonary soft tissue densities, 212–18
coaclation of the aorta, 102–15
congenital heart disease, 190–201
Ebstein’s anomaly, 174–87
imaging in, 190–201
imaging modalities, 192–4
heart magnetic resonance, 193
computed tomography, 193
positron emission tomography, 194
radionuclide angiography, 194
transthoracic echocardiography, 192–3
indications for cardiac magnetic resonance imaging, 191–2
left ventricular outflow tract obstruction, 87–98
patent ductus arteriosus, 197
and pregnancy, 237–55
case study, 237, 254–5
cyanotic, 248
fetal–neonatal risk, 241–2
Fontan palliation, 249–50
high-risk lesions, 242–3
left-to-right shunt, 243
maternal risk, 238–41
pressure overload lesions, 245–8
regurgitant valves, 244
systemic right ventricle, 248–9
volume overload lesions, 243–4
pulmonary arterial hypertension, 57–73
pulmonary stenosis, 25–38
right ventricular outflow obstruction, 25–38
right ventricular outflow tract obstruction, 197
secundum atrial septal defect, 1–7
single-ventricle physiology, 157–71
tetralogy of Fallot, 139–53
transposition of great arteries, 126–38
ventricular septal defect, 41–53
right ventricular outflow obstruction, 25–38
right ventricular outflow tract obstruction, 197
secundum atrial septal defect, 1–7
single-ventricle physiology, 157–71
tetralogy of Fallot, 139–53
transposition of great arteries, 126–38
ventricular septal defect, 41–53
congenital pulmonary stenosis, 28
congenital rubella syndrome, 28
congenitally corrected transposition of the great arteries (cTGA), 76–85
assessment and investigations, 79–80
chest radiograph, 79
echocardiography, 80
electrocardiogram, 79
associated defects, 78
associated with maternal conditions, 80
cardiac catheterization, 80
magnetic resonance imaging, 80
atrioventricular discordance, 78
case study, 76, 84–5
definition of, 76
follow-up, 84
congenitally corrected transposition of the great arteries (cTGA) (Contd.)
incidence, 78–9
incidence of arrhythmia in, 223
medical management, 80–82
issues, 81–2
LV outflow tract obstruction, 81–2
right ventricular failure, 80–81
tricuspid regurgitation, 80–81
medical management issues, 81–2
multislice CT scan of, 77f
and pregnancy, 83–4
presentation, 79
sinus rhythm, 77f
ventriculoarterial discordance, 78
connective tissue disorders, 115–18
bicuspid aortic valve, 117–18
Ehlers-Danlos syndrome, 115–16
Loeys-Dietz syndrome, 115–16
Marfan syndrome, 115–16
thoracic aortic aneurysm and dissection syndrome, 117
Turner syndrome, 117
continuous wave Doppler, 27f, 29, 48, 107f, 196f, 237
contraception, 70–71, 252–4
contraceptive pills, 252
contrast echo, 136
coronary artery disease, 113
coronary ischemia, 69–70
Coumadin, 70
crochetage, 5f
cyanotic congenital heart disease, 248
cystic medial necrosis, 115
Depo-Provera injections, 70, 254
desogestrel, 254
diastolic pressure, calculation of, 4
differential diagnosis, 182–3
direct systemic arterial collaterals, 213
double-inlet ventricle, 165–6
double-orifice left atrioventricular valve, 21
Down syndrome, 210, 211, 231
Ebstein’s anomaly, 174–87
arrhythmia intervention, 184–5
associated cardiac lesions, 180
background, 175
case study, 174–5, 187
catheter ablation, 184–5
classification, 178–9
clinical features, 179–80
diagnosis, 180–83
cardiac catheterization, 182–3
chest radiography, 181
differential diagnosis, 182–3
echocardiography, 181–2
electrocardiogram, 181
magnetic resonance imaging, 182
physical examination, 180–81
genetics, 178
imaging, 200
pathology of, 177–8
postoperative findings, 186
and pregnancy, 184
prognosis, 186
surgical indications, 185
transthoracic echocardiography, 176f
echocardiography
atrioventricular septal defects, 20–21
congenitally corrected transposition of the great arteries, 80
Ebstein’s anomaly, 181–2
transposition of great arteries, 134–6
valvular pulmonary stenosis, 29
ventricular septal defect, 47–8
Ehlers-Danlos syndrome, 115–16
Eisenmenger syndrome, 57–73
aneurysmal dilatation in, 216
cardiac examination, 64
case study, 57–8, 73
congenital lesions, 62f
contraception, 70–71
coronary ischemia, 69–70
definition of, 58
Index 265

disease-targeting therapies, 72–3
endothelin receptor blockade, 73
phosphodiesterase inhibitors, 73
prostacyclin, 72
evaluation of, 63–4
genetics, 62–3
hemostatic defects, 65–6
history, 60
intrapulmonary thromboses, 66
iron deficiency, 66
managing, 71–2
anticoagulation, 72
erthrocytosis, 72
heart–lung transplantation, 72
home oxygen, 71–2
mortality risks, 59–60
noncardiac surgery, 66–9
pathophysiology of, 62–3
pulmonary neovascularity in, 214
renal dysfunction, 69
secondary erythrocytosis, 66
in secundum atrial septic defect, 3
special investigations, 64–5
stroke risk, 66
in ventricular septal defect, 44, 51
elastases, 62
electrocardiogram, 79, 133–4, 181
endocarditis, 151
bicuspid aortic valve, 92–3
subvalvular aortic stenosis, 96
endothelin receptor blockade, 73
erthrocytosis, 66, 72
erthropoietin, 66
Essure, 254
estrogen, 70, 83, 245, 252
etonogestrel, 254
exercise test, 136
extracardiac Fontan procedure, 164f
extrapulmonary soft tissue densities, 212–18
fetal–neonatal risk, 241–2
fibronectin, 63
first heart sound (S1), 28
First Natural History Study of Congenital Heart Defects, 31
flow velocities, 136
Fontan circulation, 169–70
Fontan conversion, 171
Fontan palliation, 249–50
Gerbode defects, 42, 45, 51
Ghent nosology, 115
Glenn shunt, 161–2
glomerulopathy, 69
hematocrit, 66, 68–9
Holt-Oram syndrome, 242
home oxygen, 71
hypertension, 112
hypertrophic cardiomyopathy, 229
hyperuricemia, 69
hyperviscosity, 52, 57, 66, 67, 69, 72, 169f
hypoplastic left heart, 165
hypoxia, 67, 69
Iloprost, 72
Implanon, 70, 254
indirect systemic arterial collaterals, 213
infective endocarditis, 52
inferior vena cava, 217–18
infundibular ventricular septal defect, 42–3
inlet ventricular septal defect, 44
Inoue balloon, 31
intermediate atroventricular septal defects, 12
interventional catheterization, 110–11
intrapulmonary thromboses, 66
iron deficiency, 66
Jatene procedure, 248
Kaplan-Meier survival curves, 152f
Kartagener triad, 213
Kawashima procedure, 128
Kerley lines, 213–14
Kreutzer Fontan procedure, 158, 163
kyphosis, 211

leaflets, 19
left atrial isomerism, 167
left atrium, 42f, 145f, 177f, 218
left superior vena cava, 216–17
left ventricle
baffles, 129–32
chest x-ray, 217
congenitally corrected transposition of the great arteries, 76
displacement of, 70
double-inlet ventricle, 165
electrocardiographic view, 43f
enlargement of, 53
illustration, 42f
patent ductus arteriosus, 197
secundum atrial septic defect, 4
single-ventricle physiology, 158, 160
tetralogy of Fallot, 140f, 141f
transthoracic echocardiogram, 44f, 89f
left ventricular dysfunction, 149, 151
left ventricular outflow tract obstruction (LVOTO), 87–98
anatomical repair, 81–2
in atrioventricular septal defects, 10–11
bicupid aortic valve, 89–93
case study, 87–8, 97–8
genital abnormalities, 88
overview, 87
and pregnancy, 88–9
signs and symptoms, 88
subvalvular aortic stenosis, 93–6
supravalvular aortic stenosis, 96–7
valvular stenosis, 89–90
left ventriculography, 49
left-to-right shunt, 3, 45, 243–4
levonorgestrel, 254
Loeys-Dietz syndrome, 115–16
Lunelle, 252
LV dysfunction, 145

macroleoentry atrial tachycardia, 225f
magnetic resonance imaging (MRI), 6, 80, 107, 137, 182
maladie de Roger, 46
Marfan syndrome, 115–16
maternal risk, 238–41
matrix metalloproteinases, 62–3
MAZE procedure, 7
medroxyprogesterone acetate, 254
megakaryocytes, 65, 69
membranous ventricular septal defect, 43f
microcystosis, 66
Mirena implant, 70–71, 84, 254
mitral stenosis, 245
murmurs, 10, 16, 25, 28, 41, 46–7, 105, 133, 174
muscular ventricular septal defect, 44
Mustard atrial switch procedure, 126–38
arrhythmia, 130–31, 223f
atrial baffles, 131
baffle leaks, 132
baffle obstruction, 131–2
cardiac catheterization, 137
case study, 126, 137
contrast echo, 136
echocardiography, 134–6
electrocardiogram, 133–4
exercise test, 136
history, 133
magnetic resonance imaging, 137
overview, 128
physical examination, 133
routine follow-up, 133
schematic drawing, 128f
ventricular function, 129–30

NKX 2.5 gene defect, 231
noncardiac surgery, 66–9
Noonan syndrome, 28, 57
Norplant, 254
Norwood procedure, 161
orthodromic reciprocating tachycardia, 225f
OrthoEvra, 252
outlet chamber, 215, 219–20
pulmonary arterial hypertension (PAH) (Contd.)
managing, 71–2
anticoagulation, 72
erthrocytosis, 72
heart-lung transplantation, 72
home oxygen, 71–2
mortality risks, 59–60
noncardiac surgery, 66–9
outcomes, 59–60
pathophysiology of, 62–3
renal dysfunction, 69
secondary erythrocytosis, 66
special investigations, 64–5
stroke risk, 66
pulmonary arterial pressure, 3–4
pulmonary arteriovenous fistulae, 213
pulmonary artery banding, 161
pulmonary hypertension, 247–8
pulmonary neovascularity, 214
pulmonary regurgitation, 143, 148, 150, 244
pulmonary stenosis, 25–38
angiology, 36f
case, 25, 35
congenital, 28
murmurs in, 28
overview, 25–6
pre- and post-valvuloplasty hemodynamics, 37f
in pregnant women, 247
subvalvular, 34–5
supravalvular stenosis, 35
valvular, 26–34
pulmonary trunk, 216
pulmonary vascular resistance, 3, 63
pulmonary vascularity, increased, 2f
pulmonary venous vascularity, 213–14
QRS complex, 5f, 134
radionuclide angiography (RNA), 194
Rastelli procedure, 81–2, 128
regurgitant valves, 244
renal dysfunction, 51, 69, 170
residual RVOTO, 145, 148
residual ventricular septal defects, 145, 149
restrictive right ventricle, 143–5, 148, 150
right atrial isomerism, 167f
right atrium, 2–3, 29, 45, 127f, 128f, 131–3, 135f, 140f, 215f
right superior vena cava, 216–17
right ventricle atrioventricular septal defects, 19
dilated, 139, 145, 221
double-chambered, 34–5
echocardiogram, 44f
enlarged, 217f
hypertrophied, 33, 73, 76
illustration, 42f
imaging of, 30
normal anatomy and circulation, 127f
repair, 94
restrictive, 143, 148
secundum atrial septic defect, 3
systemic, 248–9
tetralogy of Fallot, 140, 214f
transcatheter echocardiography, 44f
unbalanced AVSD, 21
right ventricular dilatation, 143, 148, 150
right ventricular failure, 80–81
right ventricular outflow tract obstruction (RVOTO), 141–2, 197
right-to-left shunt, 3, 65, 67, 70, 133, 196, 200
Seckel syndrome, 211
second heart sound (S2), 4
Second Natural History Study of Congenital Heart Defects, 31
secundum atrial septic defect, 1–7
anatomy of, 2–3
case, 1
closure of, 6–7
diagnosis, 4–6
cardiac catheterization, 5–6
magnetic resonance imaging, 5–6
transesophageal echocardiography, 4–5
embryology of, 2–3
natural history, 3–4
pathophysiology of, 3
patient follow-up, 7
treatment of, 6–7
Senning procedure, 81–2, 248–9
septation, 2–3
Shone syndrome, 94
sildenafil, 70, 73
single left ventricular papillary muscle, 21
single photon emission computed
tomography (SPECT), 194
single-ventricle physiology, 157–71
arrhythmias in Fontan patients, 170–71,
223
clinical components of morphology, 159
definition of, 157–8
eytology, 158–9
Fontan conversion, 171
incidence, 158
initial presentation in childhood, 160
long-term implications of Fontan
circulation, 169–70
long-term outcome in adulthood, 169
in pregnant women, 249–50
presentation in adulthood, 167–9
subtypes, 165–7
atrioventricular valve atresia, 166–7
double-inlet ventricle, 165–6
heterotaxy syndromes, 166–7
hypoplastic left heart, 165
ventricular morphology, 160
single-ventricle heart, 219
sinus brachycardia, 224, 232
sinus solitus, 167
Sitaxsentan, 73
situs inversus, 167
spherocytes, 58
sternotomy, 211
subcutaneous implant, 70
subvalvular aortic stenosis (SAS), 93–6.
See also left ventricular outflow tract
obstruction (LVOTO)
congenital defects in, 93–4
endocarditis, 96
intervention, 94–5
long-term complications, 95–6
overview, 93–4
subvalvular pulmonary stenosis, 34–5
sudden cardiac death, 146–7, 150, 151,
229–31
suicide right ventricle, 32–3
superior vena cava, 216–18
supravalvar pulmonary stenosis, 35
supravalvar stenosis, 96–7
supraventricular arrhythmia, 145–6, 149,
151
supraventricular tachycardia, 223–5
surgical valvotomy, 31
systemic arterial collaterals, 213
systemic right ventricle, 248–9
systemic vascular resistance (SVR), 67–8
systolic pressure, calculation of, 4
tachyarrhythmia, 52, 130, 145
tachycardia, 223–7
Tadalafil, 73
tenascin, 63
tetralogy of Fallot, 139–53
anatomy of, 140
aneurysmal dilatation of RVOT, 145,
149, 150
aortic regurgitation, 145
case study, 139, 151
dilatation of aortic root, 149
diagnosis, 151
imaging, 197–9
incidence, 139
incidence of arrhythmia in, 223
Kaplan-Meier survival curves, 152
left atrium in, 218
left ventricular dysfunction, 149, 151
long-term complications, 143–8
LV dysfunction, 145
management of late problems, 148–50
premature ventricular contractions, 146,
149
prevention of late problems, 150–51
psychiatric issues, 147–8
pulmonary arterial vascularity in, 213
tetralogy of Fallot (Contd.)
pulmonary regurgitation, 143, 148, 150
residual RVOTO, 145, 148
residual VSDs, 145, 149
restrictive right ventricle, 143–5, 148, 150
right ventricular dilatation, 143, 148, 150
risk score, 152
sudden cardiac death, 146–7, 150, 151
supraventricular arrhythmia, 145–6, 149, 151
surgical repair, 141–3
synopsis, 153
systemic arterial collaterals in, 213
ventricular tachycardia, 146, 150, 151
thoracic aortic aneurysm and dissection syndrome, 117
thrombocytopenia, 57, 65, 68, 169
transabdominal fetal echocardiography, 242
transesophageal echocardiography (TEE), 4–5, 64
transforming growth factor beta receptor mutations (TGFBR), 116–17
transitional atrioventricular septal defects, 12
transposition of great arteries (TGA), 126–38
arrhythmia in, 130–31, 223
atrial baffles, 131
baffle leaks, 132
baffle obstruction, 131–2
cardiac catheterization, 137
case study, 126, 137
complex, 128
contrast echo, 136
echocardiography, 134–6
electrocardiogram, 133–4
exercise test, 136
history, 133
magnetic resonance imaging, 137
overview, 128
physical examination, 133
in pregnant women, 248–9
Rashkind balloon atrioseptostomy, 127
routine follow-up, 133
schematic drawing, 128
simple, 128
surgical techniques, 128–9
ventricular function, 129–30
transesophageal echocardiography (TEE), 4, 192–3
Treprostinil, 72
tricuspid annular plane systolic excursion (TAPSE), 135
tricuspid regurgitation, 52, 64, 76, 80–81, 126, 137, 143
tricuspid valve reoperation, 223
Turner syndrome, 104, 117, 246
univentricular heart, 158, 219–20
UT 15-C, 72
vaginal ring, 252
valvular pulmonary stenosis, 26–34
clinical features, 28–30
guidelines, 33–4
pathology of, 26–8
pathophysiology of, 28
and pregnancy, 33–4
prognosis, 31–3
therapeutic approach, 30–31
valvular stenosis, 34, 89–90
Vardenafil, 73
venesection, 57, 66, 67
ventricular fibrillation, 224, 323
ventricular septal defect (VSD), 41–53
in adults, 46–8
anatomy of, 41–5
cardiac examination in, 45–7
case, 41, 53–4
diagnostic tests, 49–50
echocardiogram, 48–9
imaging, 196–7
incidence of arrhythmia in, 223
indication for intervention, 50–52
infundibular, 42–3
inlet, 44
ventricular septal defect (VSD) (Contd.)
   left-to-right shunt in, 45
   membranous, 42
   muscular, 44
   pathophysiology of, 41–6
   potential late complications, 51–2
   in pregnant women, 243
   prognosis, 51–2
   spontaneous closure, 50
   surgical closure, 51
ventricular septum, segments, 42f
ventricular tachycardia, 146, 150, 151, 224f, 225–6, 232f
ventriculography, 49, 194
volume overload lesions, 243–4
Waterston shunt, 96, 142, 161, 168f
Williams syndrome, 28, 35
x-ray, chest, 208–20
   atria, 218–20
   bones, 211
   in congenitally corrected transposition of the great arteries, 79
   in Ebstein’s anomaly, 181
   extrapulmonary soft tissue densities, 212–18
   sequence for reading, 209f
<table>
<thead>
<tr>
<th>Working group member</th>
<th>Employment</th>
<th>Research grant</th>
<th>Other research support</th>
<th>Speakers bureau/honoraria</th>
<th>Expert witness</th>
<th>Ownership interest</th>
<th>Consultant/ advisory board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ammash</td>
<td>Mayo Clinic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Broberg</td>
<td>Oregon Health and Science University</td>
<td>None</td>
<td>None</td>
<td>American College of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Cetta</td>
<td>Mayo Clinic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Colman</td>
<td>University of Toronto</td>
<td>None</td>
<td>Modest</td>
<td>None</td>
<td>Modest</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Connolly</td>
<td>Mayo Clinic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Deal</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Foster</td>
<td>USCF</td>
<td>EBR Inc, Boston Scientific, Evalve Inc+</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Gatzoulis</td>
<td>Royal Brompton Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Gurvitz</td>
<td>University of California, San Francisco</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lease</td>
<td>Southampton Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lim</td>
<td>UMC St. Radboud</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Meijboom</td>
<td>Southampton Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Owusu-Anash</td>
<td>Southampton Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Perloff</td>
<td>Streisand/American Heart Association</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Phillips</td>
<td>Mayo Clinic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Silversides</td>
<td>University Health Network, Toronto, Ontario</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Siu</td>
<td>University of Western Ontario</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Swan</td>
<td>Royal Brompton Hospital, London</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Working group member</td>
<td>Employment</td>
<td>Research grant</td>
<td>Other research support</td>
<td>Speakers bureau/ honoraria</td>
<td>Expert witness</td>
<td>Ownership interest</td>
<td>Consultant/ advisory board</td>
<td>Other</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------------------------</td>
<td>----------------</td>
<td>------------------------</td>
<td>----------------------------</td>
<td>-----------------</td>
<td>---------------------</td>
<td>---------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Therrien</td>
<td>Jewish General Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Thorne</td>
<td>University Hospital, Birmingham</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Veldtman</td>
<td>Southampton University Hospital Trust</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Wald</td>
<td>Toronto General Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Webb</td>
<td>University of Pennsylvania Health Systems</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

*Modest

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire which all writing group members are required to complete and submit. A relationship is considered to be “Significant” if (a) the person receives $10,000 or more during any 12 month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “Modest” if it is less than “Significant” under the preceding definition.
The AHA Clinical Series

SERIES EDITOR • ELLIOTT ANTMAN

Biomarkers in Heart Disease
James A. de Lemos
9781405175715

Biomarkers in Heart Disease

Novel Techniques for Imaging the Heart
Cardiac MR and CT
Edited by Marcello Di Carli and Raymond Kwong
9781405175333

Novel Techniques for Imaging the Heart

Pacing to Support the Failing Heart
Kenneth A. Ellenbogen and Angelo Auricchio
9781405175340

Pacing to Support the Failing Heart

Metabolic Risk for Cardiovascular Disease
Robert H. Eckel
9781405181044

Metabolic Risk for Cardiovascular Disease

Cardiogenic Shock
G. E. Magnus Ohman and Judith Hochman
9781405179263

Cardiogenic Shock

Cardiovascular Genetics and Genomics
Dan Redin
9781405175401

Cardiovascular Genetics and Genomics

American Heart Association
Learn and Live
AHA/ASA Premium
Professional Members
Save 20%

To join and order visit
my.americanheart.org